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Background:  Inter-patient variability in stem cell repair confounds outcome of cardiac regenerative therapies. In preclinical testing, growth 
factors-guided cardiopoietic specification of human bone marrow derived mesenchymal stem cells (MSC) ensured reparative uniformity. The ensuing 
multicenter C-Cure clinical trial is designed to assess feasibility and safety of cardiopoietic (CP) MSCs therapy in ischemic heart failure.
Methods:  Forty-five patients with heart failure of ischemic origin were randomized to standard medical care or autologous CP MSCs (600-
1200x106) treatment delivered into viable but dysfunctional left ventricular (LV) segments using electromechanical guidance. All patients were on 
ICD prophylaxis.
Results:  Demographic and clinical baseline data were similar between 24 controls and 21 patients treated with CP MSCs. Delivery of CP MSCs was 
feasible without peri-procedural complications. At cumulative follow up of 7385 days (range from 235 to 564 days, median 334 days), no evidence 
of cell-induced systemic toxicity or pro-arrhythmogenicity was detected. In 18 patients with arrhythmic events, 63 episodes were detected in controls 
(2.6/patient) vs 42 episodes in the CP MSCs group (2.0/patient). Five ventricular fibrillation episodes requiring ICD shock were all detected in 
controls, and none recorded in the CP MSCs group. At 6 months follow-up, clinical performance assessed from the 6 min walk-test improved in CP 
MSCs treated patients by 52±19 m while it worsened by -21±14 m in controls (p=0.003). While left ventricular end-diastolic volumes decreased to a 
similar extent, the reduction of the end-systolic volume was 3-fold larger in the CP MSCs treated than control group (-22±4 vs -8±3 mL, p=0.01) and 
paralleled a significant increase in LV ejection fraction (5.2±0.6% vs 1±0.7%, p<0.0001).
Conclusions:  The C-Cure study demonstrates the feasibility and safety profile of administering lineage-specified mesenchymal stem cells for 
cardiac repair in ischemic cardiomyopathy. Efficacy signals related to improvements in left ventricular and clinical performance are consistent with a 
generalized therapeutic benefit.
